Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)

Phase 1/2 Terminated 50 enrolled SGX Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a phase I, single-arm, open-label, multi-center study of rising doses of Troxatyl™ whose purpose is to determine the safety, tolerance, and pharmacokinetics, and to establish the recommended infusion schedule of Troxatyl™.

Timeline

Start: 2003-04
Primary completion: 2007-06
Completion: 2007-06

Outcome

Outcome not reported

Stopped: “Trial stopped June 2007”

Publications

Background Giles FJ. Troxacitabine-based therapy of refractory leukemia. Expert Rev Anticancer Ther. 2002 Jun;2(3):261-6. doi: 10.1586/14737140.2.3.261.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Troxacitabine	Small molecule	—	—